Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23152926 | 0.85 | ECE1 (0.32) | ECE1 | |
| SCHEMBL10819618 | 0.78 | ECE1 (0.36) | ALDH1A1ECE1 | |
| SCHEMBL14537234 | 0.77 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL3194539 | 0.77 | ECE1 (0.43) | ECE1 | |
| SCHEMBL4093907 | 0.76 | LMNA (0.42) | ALDH1A1 | |
| SCHEMBL12902751 | 0.74 | KMT2A (0.43) | ALDH1A1ECE1 | |
| SCHEMBL22001621 | 0.74 | ALDH1A1 (0.35) | ALDH1A1ECE1 | |
| SCHEMBL25173385 | 0.74 | CYP2D6 (0.46) | ALDH1A1ECE1 | |
| SCHEMBL10085297 | 0.74 | KDM4E (0.48) | ALDH1A1ECE1 | |
| SCHEMBL23051663 | 0.73 | TDP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167312-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180194803-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20070123453-A1 | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion | ELI LILLY AND COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070123453-A1 | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion | ELI LILLY AND COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167312-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | MC4R, MC1R, MC2R | ALDH1A1 3549/4885ECE1 4550/4885 |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | MC4R, MC3R, MC1R | ALDH1A1 4269/4885ECE1 1433/4885 |
| US-20180194803-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | MC4R, MC1R, MC2R | ALDH1A1 3549/4885ECE1 4550/4885 |
| US-20070123453-A1 | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion | MC4R, MC5R, MC3R | ALDH1A1 3825/4885ECE1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.